Normosang (Human Hemin)

Human hemin, the active ingredient in Normosang, is a heme derivative presented as a lyophilized powder for solution for injection for intravenous use. It treats acute attacks of porphyria such as acute intermittent porphyria, hereditary coproporphyria and variegate porphyria. GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Normosang is used to manage acute porphyria attacks by providing exogenous heme to regulate the heme biosynthetic pathway. Acute intermittent porphyria: reduces neurotoxic precursor accumulation and alleviates attack symptoms. Hereditary coproporphyria: helps terminate acute episodes and decreases porphyrin precursor levels. Variegate porphyria: provides heme to control acute attacks and improve clinical stability.

Administration of Normosang may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Vomiting: occasional emesis. - Injection site pain: discomfort at the intravenous site. - Headache: mild headache. - Hypertension: temporary increase in blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hemolysis: breakdown of red blood cells, especially in patients with G6PD deficiency. - Thrombophlebitis: inflammation and clot formation at the infusion site. - Acute renal failure: sudden loss of kidney function. - Coagulopathy: impaired blood clotting.

Before using Normosang, clinicians should consider several safety and handling precautions. - Indication verification: confirm diagnosis of an acute porphyria attack. - G6PD deficiency: assess for glucose‑6‑phosphate dehydrogenase deficiency to avoid hemolysis. - Renal function: monitor kidney parameters in patients with pre‑existing renal impairment. - Concomitant drugs: review other medications that may affect heme synthesis. - Pregnancy and lactation: use only if potential benefit outweighs unknown risks. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other agents that influence heme metabolism or coagulation.

Major Interactions (Avoid): - Barbiturates: potentiate ALAS induction, reducing therapeutic effect. - Phenytoin: may increase porphyrin precursor synthesis. - Oral contraceptives containing estrogen: can exacerbate porphyria attacks.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as hemin may affect coagulation. - Iron supplements: assess iron status to avoid overload. - Other heme‑containing products: avoid concurrent use to prevent excess heme load.